BENEFITS OF TREATMENT Sample Clauses

BENEFITS OF TREATMENT. In most cases, hepatitis C will respond to treatment as determined by a blood test that measures the presence and amount of hepatitis C in the blood. If you have no hepatitis C in your blood 12 weeks after the end of treatment, this is called a “sustained virologic response” and means you no longer have hepatitis C. Your chance of achieving a sustained virologic response depends on the hepatitis C genotype, how much hepatitis C virus you have in your blood at the beginning of treatment, any past treatment response, and how much liver damage you have had prior to treatment. It is possible that you may develop some serious side effects, which will require you to stop the treatment. You may still benefit from treatment even if it does not get rid of your hepatitis C, as it may slow down the disease. You may choose to stop treatment at any time.
Sample 1Sample 2Sample 3See All (12)
AutoNDA by SimpleDocs
BENEFITS OF TREATMENT. In most cases, hepatitis C will respond to treatment as determined by a blood test that measures the presence and amount of hepatitis C in the blood. If you have no hepatitis C in your blood 12 weeks after the end of treatment, this is considered a “sustained virologic response” and in 99% of persons is a cure. Your chance of achieving a sustained virologic response depends on the hepatitis C genotype, how much hepatitis C virus you have in your blood at the beginning of treatment, any past treatment response, and how much liver damage you have had prior to treatment. It is possible that you may develop some serious side effects, which will require you to stop the treatment. You may still benefit from treatment even if it does not get rid of your hepatitis C, as it may slow down the disease. You may choose to stop treatment at any time. In Studies: Persons with genotype 2 who were treatment-naïve (never treated before) had a ≥ 95% chance of achieving a sustained virologic response after taking sofosbuvir and ribavirin for 12 weeks. Those with cirrhosis had a response rate of 83%. Two studies, Fusion and Boson, have looked at extending sofosbuvir and ribavirin treatment. Persons with genotype 2 who were treatment-experienced (previously treated) with cirrhosis and took sofosbuvir with ribavirin for 16 weeks had a response rate of 87% (13 of 15 subjects) in the Boson study and 78% (7 of 9 subjects) in the Fusion study. Those who were treatment-experienced and did not have cirrhosis had a response rate of 92% (24 of 26 subjects) in the Fusion study. Persons with genotype 3 who were treatment-naïve, regardless of cirrhosis status had a ≥ 92% response rate after taking sofosbuvir and ribavirin for 24 weeks. For those who were treatment-experienced, the response rate was 77%. For those who were treatment- experienced with cirrhosis, the response rate was 60%.
Sample 1
BENEFITS OF TREATMENT. Your recovery progress depends on a number of things, including but not limited to, the severity of your problems, other physical or health problems, drug and/or alcohol use, and how well medicine or therapy helps with the problem(s). While no promises can be made about the outcome of treatment or any therapeutic activity provided by the PRRC team, continuing healthy habits, and working together with your treatment team will help increase your chances of success. Through your participation in the PRRC, you may notice the following benefits: feeling better mentally and physically; improving your quality of life; increasing your social support; improving your relationships; and decreased hospitalizations.
Sample 1
BENEFITS OF TREATMENT. If you have no hepatitis C in your blood 12 weeks after the end of treatment, you are cured. Your chance of cure depends on the hepatitis C genotype, how much virus you have in your blood at the beginning of treatment, any past treatment response, how much liver damage you have had prior to treatment, and taking the medication every day. It is possible that you may develop some serious side effects, which will require you to stop the treatment. You may still benefit from treatment even if it does not get rid of your hepatitis C, as it may slow down the disease.
Sample 1
BENEFITS OF TREATMENT. In most cases, hepatitis C will respond to treatment as determined by a blood test that measures the presence and amount of hepatitis C in the blood. If you have no hepatitis C in your blood 12 weeks after the end of treatment, this is considered a “sustained virologic response” and in 99% of persons is a cure. Your chance of achieving a sustained virologic response depends on the hepatitis C genotype, how much hepatitis C virus you have in your blood at the beginning of treatment, any past treatment response, and how much liver damage you have had prior to treatment. It is possible that you may develop some serious side effects, which will require you to stop the treatment. You may still benefit from treatment even if it does not get rid of your hepatitis C, as it may slow down the disease. You may choose to stop treatment at any time. In Clinical Trials: Persons with genotype 1b, without cirrhosis who were treatment-naïve (never treated before) and treatment-experienced (prior treatment failed), given Viekira Pak® for 12 weeks had a 100% response (cure) rate.
Sample 1
BENEFITS OF TREATMENT. In most cases, hepatitis C will respond to treatment as determined by a blood test that measures the presence and amount of hepatitis C in the blood. If you have no hepatitis C in your blood 12 weeks after the end of treatment, this is called a “sustained virologic response” and means you no longer have hepatitis C. Your chance of achieving a sustained virologic response depends on the hepatitis C genotype, how much hepatitis C virus you have in your blood at the beginning of treatment, any past treatment response, and how much liver damage you have had prior to treatment. It is possible that you may develop some serious side effects, which will require you to stop the treatment. You may still benefit from treatment even if it does not get rid of your hepatitis C, as it may slow down the disease. You may choose to stop treatment at any time. In Clinical Trials: Persons with genotype 1a who did not have cirrhosis were treated with Viekira Pak™ (the components of Viekira XR™) and ribavirin for 12 weeks and had a 94% or better response (cure) rate. Those with genotype 1a with compensated cirrhosis treated with Viekira Pak™ and ribavirin for 24 weeks had a 95% response rate. Liver transplant recipients who were 12 months or longer after transplant and had normal liver function and mild fibrosis were given Viekira Pak™ (the components of Viekira XR™) and ribavirin for 24 weeks. Of 34 subjects, 97% (28/29) of those who were genotype 1a and 100% (5/5) of those who were genotype 1b responded.
Sample 1
BENEFITS OF TREATMENT. In most cases, hepatitis C will respond to treatment as determined by a blood test that measures the presence and amount of hepatitis C in the blood. If you have no hepatitis C in your blood 12 weeks after the end of treatment, this is called a “sustained virologic response” and means you no longer have hepatitis C. Your chance of achieving a sustained virologic response depends on the hepatitis C genotype, how much hepatitis C virus you have in your blood at the beginning of treatment, any past treatment response, and how much liver damage you have had prior to treatment. It is possible that you may develop some serious side effects, which will require you to stop the treatment. You may still benefit from treatment even if it does not get rid of your hepatitis C, as it may slow down the disease. You may choose to stop treatment at any time. In Clinical Trials: Persons with genotype 4 who did not have cirrhosis were treated with Technivie™ and ribavirin for 12 weeks and had a 100% response (cure) rate (42 of 42 persons treated).
Sample 1
AutoNDA by SimpleDocs

Related to BENEFITS OF TREATMENT

  • PRESCRIPTION MEDICATION BENEFITS, LIMITATIONS AND EXCLUSIONS The following items are limited or excluded from your Prescription Medication coverage:

  • TREATMENT OF FRINGE BENEFITS The fringe benefits are charged using the rate(s) listed in the Fringe Benefits Section of this Agreement. The fringe benefits included in the rate(s) are listed below. TREATMENT OF PAID ABSENCES Vacation, holiday, sick leave pay and other paid absences are included in salaries and wages and are claimed on grants, contracts and other agreements as part of the normal cost for salaries and wages. Separate claims are not made for the cost of these paid absences.

  • Equality of Treatment Unless otherwise provided in this Agreement, the persons specified in Article 3, who ordinarily reside in the territory of a Contracting State, shall receive equal treatment with nationals of that Contracting State in the application of the legislation of that Contracting State.

  • Equitable Treatment ICANN shall not apply standards, policies, procedures or practices arbitrarily, unjustifiably, or inequitably and shall not single out Registry Operator for disparate treatment unless justified by substantial and reasonable cause.

  • Benefits on Layoff (The following clause is applicable to full-time employees only) In the event of a lay-off of a full-time employee the Hospital shall pay its share of insured benefits premium up to three (3) months from the end of the month in which the lay-off occurs or until the laid off employee is employed elsewhere, whichever occurs first.

  • Benefits of Agreement Nothing in this Agreement or in the Certificates, expressed or implied, shall give to any Person, other than the Certificateholders and the parties hereto and their successors hereunder, any benefit or any legal or equitable right, remedy or claim under this Agreement.

  • Accounting Treatment For accounting purposes, the Merger is intended to be treated as a "purchase."

  • PORTABILITY OF BENEFITS The following benefits are portable:

  • Xxx Treatment We have not promised you any particular tax outcome from buying or holding the Note.

  • Protection, Treatment (1) Each Contracting Party shall protect within its State territory investments made in accordance with its national laws and regulations by investors of the other Contracting Party and shall not impair by unreasonable or discriminatory measures the management, maintenance, use, enjoyment, extension, sale or liquidation of such investments. In particular, each Contracting Party or its competent authorities shall issue the necessary authorisations mentioned in Article 2, paragraph (2) of this Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.